P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA

• Ewa Lech-Marańda,
• Agata Szymańska,
• Jan Zaucha,
• Gautam Borthakur,
• Scott Solomon,
• Terrence Bradley,
• Elie Mouhayar,
• Noemi Angelosanto,
• Hendrik Nogai,
• Krzysztof Brzozka,
• Tomasz Rzymski,
• Peter Littlewood,
• Kamil Kus,
• Renata Dudziak,
• Axel Glasmacher,
• Howard Burris,
• Camille Abboud

Affiliations

Ewa Lech-Marańda

1 Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Agata Szymańska

2 Medical University of Gdansk, Gdansk, Poland

Jan Zaucha

2 Medical University of Gdansk, Gdansk, Poland

Gautam Borthakur

3 MD Anderson Cancer Center, Houston, United States

Scott Solomon

4 Northside Hospital Cancer Center, Atlanta, United States

Terrence Bradley

5 Silvester Comprehensive Cancer Center, Miami, United States

Elie Mouhayar

3 MD Anderson Cancer Center, Houston, United States

Noemi Angelosanto

6 Ryvu Therapeutics, Krakow, Poland

Hendrik Nogai

6 Ryvu Therapeutics, Krakow, Poland

Krzysztof Brzozka

6 Ryvu Therapeutics, Krakow, Poland

Tomasz Rzymski

6 Ryvu Therapeutics, Krakow, Poland

Peter Littlewood

6 Ryvu Therapeutics, Krakow, Poland

Kamil Kus

6 Ryvu Therapeutics, Krakow, Poland

Renata Dudziak

6 Ryvu Therapeutics, Krakow, Poland

Axel Glasmacher

7 University Clinic Bonn, Internal Medicine III, Bonn, Germany

Howard Burris

8 Sarah Cannon Research Institute, Nashville, United States

Camille Abboud

9 Washington University in St Louis, St Louis, United States